DPP4 inhibition attenuates filtration barrier injury and oxidant stress in the zucker obese rat

Obesity

Volumn 22, Issue 10, 2014, Pages 2172-2179

  Nistala, Ravi ^a,b,c,d,e   Habibi, Javad ^a,b,c,e,f   Aroor, Annayya ^a,b,c,e,f   Sowers, James R ^a,b,c,e,f,g   Hayden, Melvin R ^a,b,c,f   Meuth, Alex ^a,b,c,d,e   Knight, William ^a,b,c,e,f   Hancock, Tamara ^e,h   Klein, Thomas ⁱ   DeMarco, Vincent G ^a,b,c,e,f,g   Whaley Connell, Adam ^a,b,c,d,e,f  

^a University of Missouri   (United States)

^b Diabetes and Cardiovascular Center   (United States)

^c Department of Internal Medicine ^*  (United States)

^d Divisions of Nephrology and Hypertension   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f Divisions of Endocrinology and Metabolism   (United States)

^g UNIVERSITY OF MISSOURI   (United States)

^h UNIVERSITY OF MISSOURI   (United States)

ⁱ BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE 1; LINAGLIPTIN; MAMMALIAN TARGET OF RAPAMYCIN; NEPHRIN; STROMAL CELL DERIVED FACTOR 1ALPHA; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; GLOMERULAR FILTRATION BARRIER; GLOMERULOPATHY; KIDNEY HYPERTROPHY; KIDNEY INJURY; MALE; NONHUMAN; OBESITY; OXIDATIVE STRESS; PODOCYTE; PROTEIN PHOSPHORYLATION; PROTEINURIA; RAT; ZUCKER RAT; ANIMAL; DRUG EFFECTS; GLOMERULUS; INJURIES; KIDNEY DISEASE; METABOLISM; PATHOLOGY;

ANIMALS; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLOMERULAR FILTRATION BARRIER; GLUCAGON-LIKE PEPTIDE 1; HYPOGLYCEMIC AGENTS; KIDNEY DISEASES; KIDNEY GLOMERULUS; MALE; OBESITY; OXIDATIVE STRESS; PODOCYTES; RATS; RATS, ZUCKER;

EID: 84907883358     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1002/oby.20833     Document Type: Article

References (40)

1. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006; 295:1549-1555.
2. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010;303:235-241.
3. Iseki K, Ikemiya Y, Kinjo K, Inoue T, Iseki C, Takishita S. Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney Int 2004;65:1870-1876.
4. Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol 2005;16:2134-2140.
5. Sowers JR, Whaley-Connell A, Hayden MR. The role of overweight and obesity in the cardiorenal syndrome. Cardiorenal Med 2011;1:5-12.
6. Wahba IM, Mak RH. Obesity and obesity-initiated metabolic syndrome: mechanistic links to chronic kidney disease. Clin J Am Soc Nephrol 2007;2:550-562.
7. Aroor A, McKarns S, Nistala R, DeMarco V, Gardner M, Garcia-Touza M, et al. DPP-4 inhibitors as therapeutic modulators of immune cell function and associated cardiovascular and renal insulin resistance in obesity and diabetes. Cardiorenal Med 2013;3:48-56.
8. Hocher B, Reichetzeder C, Alter ML. Renal and cardiac effects of DPP4 inhibitors: from preclinical development to clinical research. Kidney Blood Press Res 2012;36:65-84.
9. Lambeir AM, Durinx C, Scharpe S, De Meester I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 2003;40:209-294.
10. Dekan G, Miettinen A, Schnabel E, Farquhar MG. Binding of monoclonal antibodies to glomerular endothelium, slit membranes, and epithelium after in vivo injection. Localization of antigens and bound IgGs by immunoelectron microscopy. Am J Pathol 1990;137:913-927.
11. Yang J, Campitelli J, Hu G, Lin Y, Luo J, Xue C. Increase in DPP-IV in the intestine, liver and kidney of the rat treated with high fat diet and streptozotocin. Life Sci 2007;81:272-279.
12. Lugari R, Dei CA, Ugolotti D, Barilli AL, Camellini C, Ganzerla GC, et al. Glucagon-like peptide 1 (GLP-1) secretion and plasma dipeptidyl peptidase IV (DPP-IV) activity in morbidly obese patients undergoing biliopancreatic diversion. Horm Metab Res 2004;36:111-115.
13. Lamers D, Famulla S, Wronkowitz N, Hartwig S, Lehr S, Ouwens DM, et al. Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes 2011;60:1917-1925.
14. Nistala R, Habibi J, Lastra G, Manrique C, Aroor AR, Hayden MR, et al. Prevention of obesity induced renal injury in male mice by DPP4 inhibition. Endocrinology. 2014:en20131920.
15. Glorie LL, Verhulst A, Matheeussen V, Baerts L, Magielse J, Hermans N, et al. DPP4 inhibition improves functional outcome after renal ischemia-reperfusion injury. Am J Physiol Renal Physiol 2012;303:F681-F688.
16. Alter ML, Ott IM, von Websky K, Tsuprykov O, Sharkovska Y, Krause-Relle K, et al. DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy. Kidney Blood Press Res 2012;36:119-130.
17. Wang Y, Landheer S, van Gilst WH, van Amerongen A, Hammes HP, Henning RH, et al. Attenuation of renovascular damage in Zucker diabetic fatty rat by NWT-03, an egg protein hydrolysate with ACE- and DPP4-inhibitory Activity. PLoS One. 2012;7:e46781.
18. 2induced oxidative stress in isolated cardiomyocytes. PLoS One 2013;8:e54518.
19. Whaley-Connell A, Demarco VG, Lastra G, Manrique C, Nistala R, Cooper SA, et al. Insulin resistance, oxidative stress, and podocyte injury: role of rosuvastatin modulation of filtration barrier injury. Am J Nephrol 2008;28:67-75.
20. Hayashi K, Kanda T, Homma K, Tokuyama H, Okubo K, Takamatsu I, et al. Altered renal microvascular response in Zucker obese rats. Metabolism 2002;51:1553-1561.
21. Zdychová J, Kazdová L, Pelikanová T, Lindsley JN, Anderson S, Komers R. Renal activity of Akt kinase in obese Zucker rats. Exp Biol Med 2008;233:1231-1241.
22. Thomas L, Eckhardt M, Langkopf E, Tadayyon M, Himmelsbach F, Mark M. (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Exp Ther 2008;325:175-182.
23. Huttner S, Graefe-Mody EU, Withopf B, Ring A, Dugi KA. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers. J Clin Pharmacol 2008;48:1171-1178.
24. Aroor AR, Sowers JR, Bender SB, Nistala R, Garro M, Mugerfeld I, et al. Dipeptidylpeptidase inhibition is associated with improvement in blood pressure and diastolic function in insulin-resistant male zucker obese rats. Endocrinology 2013;154:2501-2513.
25. Whaley-Connell A, Habibi J, Nistala R, Hayden MR, Pulakat L, Sinak C, et al. Combination of direct renin inhibition with angiotensin type 1 receptor blockade improves aldosterone but does not improve kidney injury in the transgenic Ren2 rat. Regul Pept 2012;176:36-44.
26. Hocher B, Sharkovska Y, Mark M, Klein T, Pfab T. The novel DPP-4 inhibitors linagliptin and BI 14361 reduce infarct size after myocardial ischemia/reperfusion in rats. Int J Cardiol 2013;167:87-93.
27. Fadini GP, Boscaro E, Albiero M, Menegazzo L, Frison V, de Kreutzenberg S, et al. The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha. Diabetes Care 2010;33:1607-1609.
28. Jones N, New LA, Fortino MA, Eremina V, Ruston J, Blasutig IM, et al. Nck proteins maintain the adult glomerular filtration barrier. J Am Soc Nephrol 2009;20:1533-1543.
29. Kodera R, Shikata K, Kataoka HU, Takatsuka T, Miyamoto S, Sasaki M, et al. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia 2011;54:965-978.
30. Drucker DJ. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes. Preclinical biology and mechanism of action. Diabet Care 2007;30:1335-1343.
31. De La Luz Sierra M, Yang F, Narazaki M, Salvucci O, Davis D, Yarchoan R, Zhang HH, Fales H, Tosato G. Differential processing of stromal-derived factor-1alpha and stromal-derived factor-1beta explains functional diversity. Blood 2004;103:2452-2459.
32. Salvucci O, Yao L, Villalba S, Sajewicz A, Pittaluga S, Tosato G. Regulation of endothelial cell branching morphogenesis by endogenous chemokine stromal-derived factor-1. Blood 2002;99:2703-2711.
33. Lieberthal W, Levine, JS. The role of the mammalian target of rapamycin (mTOR) in renal disease. J Am Soc Nephrol 2009;20:2493-2502.
34. Dey N, Ghosh-Choudhury N, Das F, Li X, Venkatesan B, Barnes JL, Kasinath BS, Ghosh Choudhury G. PRAS40 acts as a nodal regulator of high glucose-induced TORC1 activation in glomerular mesangial cell hypertrophy. J Cell Physiol 2010;225:27-41.
35. Sarbassov DD, Sabatini DM. Redox regulation of the nutrient-sensitive raptor-mTOR pathway and complex. J Biol Chem 2005;280:39505-39509.
36. Poirier B, Lannaud-Bournoville M, Conti M. Oxidative stress occurs in absence of hyperglycaemia and inflammation in the onset of kidney lesions in normotensive obese rats. Nephrol Dial Transplant 2000;15:467-476.
37. Zhang M, Gao X, Wu J. Oxidized high-density lipoprotein enhances inflammatory activity in rat mesangial cells. Diabetes Metab Res Rev 2010:26:455-463.
38. Quigley JE, Elmarakby AA, Knight SF, Manhiani MM, Stepp DW, Olearzcyk JJ, et al. Obesity induced renal oxidative stress contributes to renal injury in salt-sensitive hypertension. Clin Exp Pharmacol Physiol 2009;36:724-728.
39. Alter ML, Ott IM, von Websky K, Tsuprykov O, Sharkovska Y, et al. DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy. Kidney Blood Press Res 2012;36:119-130.
40. Ishibashi Y, Matsui T, Maeda S, Higashimoto Y, Yamagishi SI. Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor. Cardiovasc Diabetol 2013;12:125.